pharmaphorum

MAY 27, 2022

This is the second in a two-part series examining how pharma can embrace the DEI agenda to create more effective medicines through more representative clinical trials. There is a huge opportunity for pharma companies to capitalise on by focusing on increased DEI in clinical trials. What comes next? About the interviewees.

Clinical Trials 78

Clinical Trials Clinical Trials Trials Packaging 78

XTalks

DECEMBER 13, 2023

Now, let’s delve into the list of the top ten fastest growing biotech companies in 2023, ranked by their compound annual growth rate (CAGR). These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times.

Genetics 111

Genetics Vaccination Vaccine DNA 111

pharmaphorum

MARCH 26, 2021

The UK Government and EU Commission trumpeted their Brexit trade deal, struck at the end of December, as ‘comprehensive’, the ‘biggest yet’ But a closer inspection of the EU-UK Trade and Cooperation Agreement (TCA) renders these statements largely illusory for the pharma sector. Medical devices do not feature at all.

Production 93

Production Medicine Marketing Regulation 93

pharmaphorum

SEPTEMBER 18, 2020

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.

Pharma Companies 113

Pharma Companies Sales Vaccination Vaccine 113

pharmaphorum

DECEMBER 16, 2022

She continued to say that the stockpiling of vaccines and treatments in richer nations had left other nations without access to lifesaving medicine. This could mean that the pharma companies would need to disclose pricing and contractual terms for pandemic products, as well as mechanisms to transfer technology and expertise.

Vaccination 78

Vaccination Vaccine Production Licensing 78

pharmaphorum

AUGUST 25, 2021

Remdesivir was the first antiviral drug to receive conditional marketing authorisation in the UK by its producer, Gilead Sciences. It’s now globally accessible due to Gilead’s work with a network of generic manufacturers and their ability to sign licensing agreements just days after the US FDA registered its authorisation.

Marketing 52

Marketing Licensing Licensing Manufacturing 52

pharmaphorum

MAY 14, 2021

Read below for a preview: One of the earliest and most pronounced impacts of the UK’s vote to leave the European Union was the loss of the European Medicines Agency (EMA). NICE has always been a great reference in HTA for cost-effectiveness analysis (CEA) and cost-utility analysis (CUA) of new medicines,” he says.

Marketing 57

Marketing Regulation Medicine Life Science 57

Pharmaceutical Technology

MAY 26, 2023

After raising $125m in 2021 to redevelop the facility, more recently Touchlight secured an additional $17.3m (£14m) from the UK government’s Life Sciences Innovative Manufacturing Fund to accelerate its expansion plans and scale-up equipment. Rapid production will potentially enable researchers to overcome an industry bottleneck.

DNA 130

DNA Manufacturing Gene Therapy Gene 130

Drug Discovery World

OCTOBER 7, 2022

It is about going faster in progressing our innovation to market, taking things further along the value chain as we de-risk the early science. It’s about working together with our partners in the life science sector to get world class innovations to patients. . Hamish Ryder. Our commercial setup is rare. Tony Hickson.

HR 52

HR Research Drugs Development 52

pharmaphorum

APRIL 19, 2022

In 2022, pharma is truly a global industry, and innovation can come from anywhere. But for small life sciences outside of the USA and Europe, it can still be challenging to break onto this global stage. The company recently raised $16.5 The company’s second drug candidate, RCI002, is focused on chronic pain.

Marketing 52

Marketing Clinical Trials Clinical Trials Licensing 52